依达拉奉注射液联合瓜蒌皮注射液治疗急性缺血性脑卒中的临床研究  

Clinical trial of edaravone injection combined with Gualoupi injection in the treatment of acute ischemic stroke

作　　者：王爱岳[1] 李强[2] 余丹[1] 周治平[1] 

机构地区：[1]海口市人民医院神经内科,海口570208 [2]海南省农垦总局医院神经外科,海口570311

出　　处：《中国临床药理学杂志》2017年第15期1394-1396,共3页The Chinese Journal of Clinical Pharmacology

基　　金：海南省自然科学基金资助项目(814375)

摘　　要：目的观察依达拉奉注射液联合瓜蒌皮注射液治疗急性缺血性脑卒中的临床疗效及安全性。方法将134例急性缺血性脑卒中患者随机分为对照组67例和试验组67例。对照组予以依达拉奉注射液30 mg,qd,静脉滴注;试验组在对照组治疗的基础上,予以瓜蒌皮注射液20 m L,qd,静脉滴注。2组患者均治疗12 d。比较2组患者的临床疗效、神经功能缺损(NIHSS)评分和生活自理能力(BI)评分、C反应蛋白(CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为92.54%(62/67例)和76.12%(51/67例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的NIHSS评分分别为(11.91±2.33)和(13.21±3.35)分,BI评估量表评分分别为(62.32±12.83)和(52.72±16.53)分,CRP分别为(3.92±1.15)和(7.12±1.96)mg·d L-1,IL-6分别为(15.54±4.93)和(19.23±3.84)ng·L-1,TNF-α分别为(26.85±8.75)和(43.73±12.52)ng·m L-1,差异均有统计学意义(均P<0.05)。试验期间,2组患者均未发生药物不良反应。结论依达拉奉注射液联合瓜蒌皮注射液治疗急性缺血性脑卒中的临床疗效确切,其能明显降低患者的神经功能缺损程度,改善血清炎症因子水平,且安全性较高。Objective To observe the clinical efficacy and safety of edaravone injection combined with Gualoupi injection in the treatment of acute ischemic stroke（ AIS）. Methods A total of 134 patients with AIS were randomly divided into control group（ n = 67 cases） and treatment group（ n = 67 cases）. Control group was treated with edaravone injection 30 mg,qd,intravenous infusion. Treatment group was given Gualoupi injection of 20 m L,qd,intravenous infusion, on the basis of control group. Two groups were treated for 12 days. The clinical efficacy,the scores of National Institute of Health stroke scale（ NIHSS） and Barthel index（ BI）,the levels of C-reactive protein（ CRP）,interleukin-6（ IL-6） and tumor necrosis factor-α（ TNF-α）,adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of the treatment and control groups were 92. 54%（ 62/67 cases） and 76. 12%（ 51/67 cases） with statistically significant difference（ P〈0. 05）. After treatment,the main indexes in treatmentand control groups were compared： NIHSS scores were（ 11. 91 ± 2. 33）,（ 13. 21 ± 3. 35） points; BI scores were（ 62. 32 ± 12. 83）,（ 52. 72 ± 16. 53） points; CRP were（ 3. 92 ± 1. 15）,（ 7. 12 ± 1. 96） mg·d L^-1; IL-6 were（ 15. 54 ± 4. 93）,（ 19. 23 ± 3. 84） ng·L^-1; TNF-α were（ 26. 85 ± 8. 75）,（ 43. 73 ± 12. 52） ng ·m L^-1,the differences were statistically significant（ all P〈0. 05）. There were no adverse drug reactions occurred during the treatment. Conclusion Edaravone injection combined with Gualoupi injection has a definitive clinical efficacy and safety in the treatment of AIS,which can reduce the degree of neurological deficits,and improve the serum levels of inflammatory factors.

关 键 词：依拉达奉注射液 瓜蒌皮注射液 急性缺血性脑卒中 安全性 

分 类 号：R972[医药卫生—药品]